UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs reported Q1 FY26 total revenue from operations of ₹483.58 lakhs, up ~68% YoY from ₹287.73 lakhs in Q1 FY25 but down ~7% QoQ from ₹521.96 lakhs in Q4 FY25. Net profit fell sharply to just ₹2.11 lakhs (vs ₹36.79 lakhs in Q1 FY25 and ₹15.19 lakhs in Q4 FY25), with EPS at ₹0.04. The company noted that part of its manufacturing facility remains under suspension and upgradation, which impacted turnover for the entire quarter. The statutory auditor (Subhash Chand Jain Anurag & Associates) issued an unmodified limited review report but specifically drew attention to Note 6 regarding the facility suspension.
Despite strong YoY revenue growth, the collapse in profitability (PAT down ~94% YoY) and the ongoing facility suspension are concerns. Shareholders should monitor the timeline for resumption of the suspended manufacturing unit, as its restoration is critical to sustaining revenue and improving margins.